Aytu BioPharma (LTS:0A8M) Institutional Ownership : 1.36% (As of Apr. 17, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Aytu BioPharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aytu BioPharma's institutional ownership is 1.36%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aytu BioPharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aytu BioPharma's Float Percentage Of Total Shares Outstanding is 80.03%.

Aytu BioPharma Institutional Ownership Historical Data

The historical data trend for Aytu BioPharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Institutional Ownership Chart

Aytu BioPharma Historical Data

The historical data trend for Aytu BioPharma can be seen below:

	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Institutional Ownership	1.46	1.39	1.35	1.54	1.56	1.51	1.36	1.36	1.36	1.36

Aytu BioPharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Aytu BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (LTS:0A8M) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

AYTU:USA

Address

7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237

Website

https://www.aytubio.com

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines